IDEXX Laboratories (IDXX) Releases Quarterly Earnings, Beats Expectations By $0.01 EPS

IDEXX Laboratories (IDXX) issued its quarterly earnings data on Friday. The company reported $0.72 earnings per share for the quarter, beating the Thomson Reuters consensus estimate of $0.71 by $0.01. The company’s quarterly revenue was up 10.2% on a year-over-year basis.

IDXX has been the subject of a number of other recent research reports. Analysts at Feltl & Co. raised their price target on shares of IDEXX Laboratories from $87.50 to $90.00 in a research note to investors on Monday. They now have a “hold” rating on the stock. On the ratings front, analysts at Leerink upgraded shares of IDEXX Laboratories from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of IDEXX Laboratories from $93.00 to $94.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.

IDEXX Laboratories (IDXX) traded up 0.39% on Tuesday, hitting $85.49. IDEXX Laboratories (IDXX) has a 1-year low of $63.83 and a 1-year high of $89.50. The company has a market cap of $4.705 billion and a price-to-earnings ratio of 29.55.

IDEXX Laboratories, Inc. (IDEXX) develops, manufactures and distributes products, and provides services primarily for the veterinary and the production animal, water testing and dairy markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. IDEXX’s primary products and services include point-of-care veterinary diagnostic products, comprising rapid assays, and instruments and consumables; veterinary laboratory diagnostic and consulting services used by veterinarians; practice information systems and services, and digital radiography systems used by veterinarians; diagnostic and health-monitoring products for production animals; products that test water for certain microbiological contaminants; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.

Stay ahead of the market with Analyst Ratings Network's daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register now.

Posted by Web Inquirer Staff on 24 Apr 2012. Filed under Markets. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.